David Charles Lubner Insider Trading Transactions
Get free email notifications about insider trading for David Charles Lubner.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David Charles Lubner. David Charles Lubner is SVP and CFO in TETRAPHASE PHARMACEUTICALS INC ($TTPH) and EVP & CFO in Ra Pharmaceuticals, Inc. ($RARX) and Executive V.P. & CFO in Ra Pharmaceuticals, Inc. ($RARX) and Executive VP and CFO in Ra Pharmaceuticals, Inc. ($RARX) and Director in Nightstar Therapeutics plc ($NITE) and Director in Vor Biopharma Inc. ($VOR) and Director in Gemini Therapeutics, Inc. /DE ($FSDC) and Director in Dyne Therapeutics, Inc. ($DYN).
Latest Insider Trading Transactions of David Charles Lubner
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DYN, FSDC, NITE, RARX, TTPH, VOR
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 27 2021 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Option Exercise | A | 19.56 | 19,596 | 383,298 | 19,596 | |
Apr 07 2021 | FSDC | Gemini Therapeutic ... | Lubner David Charles | Director | Option Exercise | A | 12.66 | 58,855 | 745,104 | 58,855 | |
Mar 15 2021 | FSDC | Gemini Therapeutic ... | Lubner David Charles | Director | Option Exercise | A | 17.00 | 25,000 | 425,000 | 25,000 | |
Feb 09 2021 | VOR | Vor Biopharma Inc. | Lubner David Charles | Director | Option Exercise | A | 18.00 | 16,900 | 304,200 | 16,900 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Option Exercise | C | 0.00 | 177,872 | 0 | 0 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Option Exercise | P | 0.00 | 177,872 | 0 | 177,872 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Option Exercise | A | 5.54 | 14,444 | 80,020 | 14,444 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Option Exercise | A | 5.54 | 11,156 | 61,804 | 11,156 | |
Sep 23 2020 | DYN | Dyne Therapeutics, ... | Lubner David Charles | Director | Buy | C | 0.00 | 53,625 | 0 | 53,625 | 0 to 53.6 K |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 0.00 | 10,416 | 0 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 21.00 | 133,000 | 2,793,000 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 7.33 | 62,500 | 458,125 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 16.64 | 112,500 | 1,872,000 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 5.60 | 28,571 | 159,998 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 2.87 | 92,283 | 264,852 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 2.87 | 115,572 | 331,692 | 0 | |
Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Sell | D | 48.00 | 15,622 | 749,856 | 0 | 15.6 K to 0 (-100.00 %) |
Jun 07 2019 | NITE | Nightstar Therapeu ... | Lubner David Charles | Director | Option Exercise | D | 13.57 | 21,000 | 284,970 | 0 | |
Jun 07 2019 | NITE | Nightstar Therapeu ... | Lubner David Charles | Director | Option Exercise | D | 12.27 | 18,200 | 223,314 | 0 | |
Jun 07 2019 | NITE | Nightstar Therapeu ... | Lubner David Charles | Director | Sell | D | 25.50 | 29,124 | 742,662 | 0 | 29.1 K to 0 (-100.00 %) |
Feb 05 2019 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Option Exercise | M | 0.00 | 10,417 | 0 | 20,833 | |
Feb 05 2019 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Option Exercise | A | 21.00 | 133,000 | 2,793,000 | 133,000 | |
Feb 05 2019 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Payment of Exercise | F | 21.00 | 3,291 | 69,111 | 7,126 | 10.4 K to 7.1 K (-31.59 %) |
Feb 05 2019 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Buy | M | 0.00 | 10,417 | 0 | 10,417 | 0 to 10.4 K |
Jan 29 2019 | NITE | Nightstar Therapeu ... | Lubner David Charles | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
Jan 29 2019 | NITE | Nightstar Therapeu ... | Lubner David Charles | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
Feb 05 2018 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Option Exercise | A | 0.00 | 31,250 | 0 | 31,250 | |
Feb 05 2018 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Option Exercise | A | 7.33 | 62,500 | 458,125 | 62,500 | |
Feb 03 2017 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive V.P. & CF ... | Option Exercise | A | 16.64 | 112,500 | 1,872,000 | 112,500 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | EVP & CFO | Option Exercise | A | 2.87 | 29,285 | 84,048 | 29,285 | |
Aug 17 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 7.94 | 9,500 | 75,430 | 123,799 | |
Aug 17 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 42.92 | 9,500 | 407,740 | 69,270 | 78.8 K to 69.3 K (-12.06 %) |
Aug 17 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 7.94 | 9,500 | 75,430 | 78,770 | 69.3 K to 78.8 K (+13.71 %) |
Jul 15 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 7.94 | 1,701 | 13,506 | 133,299 | |
Jul 15 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 5,799 | 11,772 | 13,744 | |
Jul 15 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 48.92 | 7,500 | 366,900 | 69,270 | 76.8 K to 69.3 K (-9.77 %) |
Jul 15 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 7.94 | 1,701 | 13,506 | 76,770 | 75.1 K to 76.8 K (+2.27 %) |
Jul 15 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 5,799 | 11,772 | 75,069 | 69.3 K to 75.1 K (+8.37 %) |
Jun 16 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 7,500 | 15,225 | 19,543 | |
Jun 16 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 41.67 | 7,500 | 312,525 | 69,270 | 76.8 K to 69.3 K (-9.77 %) |
Jun 16 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 7,500 | 15,225 | 76,770 | 69.3 K to 76.8 K (+10.83 %) |
Jun 16 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 41.29 | 10,000 | 412,900 | 69,270 | 79.3 K to 69.3 K (-12.62 %) |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 7,316 | 14,851 | 27,043 | |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 7,684 | 15,599 | 0 | |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 39.28 | 7,316 | 287,372 | 79,270 | 86.6 K to 79.3 K (-8.45 %) |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 7,316 | 14,851 | 86,586 | 79.3 K to 86.6 K (+9.23 %) |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 39.28 | 7,684 | 301,828 | 79,270 | 87 K to 79.3 K (-8.84 %) |
May 18 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 7,684 | 15,599 | 86,954 | 79.3 K to 87 K (+9.69 %) |
Jan 09 2015 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | A | 39.94 | 100,000 | 3,994,000 | 100,000 | |
Jun 18 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 12.51 | 13,530 | 169,260 | 78,463 | 92 K to 78.5 K (-14.71 %) |
Mar 10 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 13.65 | 4,510 | 61,562 | 91,993 | 96.5 K to 92 K (-4.67 %) |
Feb 13 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 13.92 | 4,506 | 62,724 | 96,503 | 101 K to 96.5 K (-4.46 %) |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 20,614 | 41,846 | 34,359 | |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 2.03 | 33,295 | 67,589 | 7,684 | |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | M | 0.87 | 34,482 | 29,999 | 0 | |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Sell | S | 14.22 | 9,928 | 141,176 | 101,009 | 110.9 K to 101 K (-8.95 %) |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 20,614 | 41,846 | 110,937 | 90.3 K to 110.9 K (+22.82 %) |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 2.03 | 33,295 | 67,589 | 90,323 | 57 K to 90.3 K (+58.38 %) |
Feb 11 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | M | 0.87 | 34,482 | 29,999 | 57,028 | 22.5 K to 57 K (+152.94 %) |
Jan 10 2014 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | A | 14.99 | 100,000 | 1,499,000 | 100,000 | |
May 17 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | A | 7.94 | 135,000 | 1,071,900 | 135,000 | |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | C | 0.00 | 116,686 | 0 | 0 | |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | C | 0.00 | 115,000 | 0 | 0 | |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | C | 0.00 | 52,173 | 0 | 0 | |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Option Exercise | C | 0.00 | 40,000 | 0 | 0 | |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | C | 0.00 | 4,023 | 0 | 22,546 | 18.5 K to 22.5 K (+21.72 %) |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | C | 0.00 | 3,096 | 0 | 18,523 | 15.4 K to 18.5 K (+20.07 %) |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | C | 0.00 | 1,799 | 0 | 14,557 | 12.8 K to 14.6 K (+14.10 %) |
Mar 27 2013 | TTPH | TETRAPHASE PHARMAC ... | Lubner David Charles | SVP and CFO | Buy | C | 0.00 | 1,379 | 0 | 12,758 | 11.4 K to 12.8 K (+12.12 %) |
Page: 1